Dynal Biotech acquisition completed


All the acquisition terms having been met, Ratos is now completing its acquisition together with Nordic Capital of the Norwegian biotechnology company Dynal Biotech. Ratos will pay a purchase price of NOK 242m for a 25% stake in Dynal Biotech.
"Dynal Biotech is already a well-established, profitable company in the biotechnology sector. We also see attractive opportunities within the company's R&D," says Ratos's CEO Arne Karlsson.

Dynal Biotech (www.dynalbiotech.com) is world leading within research, development and production of magnetic and non-magnetic very small completely spherical polymer beads, and markets a wide range of products based on its technology. Among the applications is separation of biological substances. The company has customers and partners within industry as well as research, mainly in the diagnostics, genomics and cell therapy sectors. Dynal's main site is in Oslo. Its products are sold through subsidiaries and distributors in more than 30 countries. In 2000, it had a turnover of NOK 353m. The company employs approximately 230 people.

For further information, please contact:

Arne Karlsson, CEO, +46 8 700 17 00
Clara Bolinder-Lundberg, Head of Corporate Communications, +46 8 700 17 49